Axsome Therapeutics (AXSM) PT Lowered to $123 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Price: $137.78 -1.31%
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
RBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $123.00 (from $126.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Axsome Therapeutics (AXSM) PT Lowered to $250 at Guggenheim
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
- Axsome Therapeutics (AXSM) PT Lowered to $239 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
